 Capricor Therapeutics NASDAQ: CAPR has signed an exclusive, worldwide licensing agreement with Johns Hopkins University JHU to include engineered exosomes for vaccines and therapeutics as part of the Companys exosome technology portfolio. Under the terms of the agreement, Capricor has exclusive rights to develop, manufacture, and commercialize, with the right to sublicense, IP related to exosome technology for applications across both vaccine and therapeutic areas. 